NHS to Incentivize GPs to Prescribe Weight-Loss Medications
The Department of Health and Social Care (DHSC) has announced a new initiative to improve access to weight-loss support and medications through general practitioners (GPs) in England. A £25 million investment will incentivize GPs to prescribe weight-loss drugs as part of a broader effort to shift the NHS focus towards preventative healthcare.
Expanding Access to Obesity Care
Currently, access to weight-loss medications varies across GP practices. The new measures, integrated into the 2026/2027 GP contract, will add two new indicators to the Quality and Outcomes Framework (QOF). The QOF is a voluntary annual incentive program for GP practices, and these new indicators will specifically track the provision of obesity care to eligible patients.
Health Secretary Wes Streeting emphasized the need to address the growing issue of unregulated weight-loss treatments. He highlighted concerns about individuals purchasing medications privately and the risks associated with unlicensed drugs and “rogue prescribers.”
Available Medications
Mounjaro (tirzepatide), manufactured by Eli Lilly, is available for prescription by GPs. Wegovy (semaglutide), produced by Novo Nordisk, is currently accessible through specialist weight management services.
Pharmacy Calls for Expanded Role in Weight Management
Although the DHSC focuses on incentivizing GPs, pharmacy representatives argue that community pharmacies are better positioned to deliver weight-loss services. Henry Gregg, chief executive of the National Pharmacy Association (NPA), noted the slow rollout of NHS weight-loss treatments and suggested that pharmacies could significantly increase access for patients.
Public Support for Pharmacy-Led Services
A poll commissioned by the NPA in summer 2025 revealed that 44% of UK adults would support NHS weight-loss services being delivered through community pharmacies. Leyla Hannbeck, chief executive of the Independent Pharmacies Association, highlighted the success rates of patients utilizing community pharmacy weight-loss management services.
Pilot Programs and Joint Funding
The DHSC announced in August 2025 that pilot programs for community pharmacy weight management could begin in summer 2026. These pilots will be jointly funded by the UK government and Eli Lilly, the manufacturer of Mounjaro.
Future Trends and Implications
The move to expand access to weight-loss medications through both GPs and potentially pharmacies signals a growing recognition of the importance of addressing obesity as a public health priority. This shift towards preventative care could have significant long-term implications for the NHS, potentially reducing the burden of obesity-related illnesses.
The involvement of pharmaceutical companies in funding pilot programs raises questions about potential conflicts of interest, but also demonstrates a collaborative approach to tackling a complex health challenge.
Did you know?
GPs in the UK have evolved from being simply “health gatekeepers” to “health agents” proactively providing preventative care services, including immunizations and health monitoring.
FAQ
Q: What medications will be available through GPs?
A: Mounjaro (tirzepatide) can be prescribed by GPs.
Q: Where can I access Wegovy?
A: Wegovy is currently available through specialist weight management services.
Q: What is the Quality and Outcomes Framework (QOF)?
A: The QOF is a voluntary annual incentive program for GP practices in England.
Q: What is the NPA’s position on weight-loss services?
A: The NPA believes community pharmacies are well-placed to deliver accessible and effective weight-loss management services.
Q: Will pharmacies be offering weight-loss services soon?
A: Pilot programs for community pharmacy weight management are planned to start in summer 2026.
Pro Tip: Discuss your weight-loss options with your GP to determine the most appropriate treatment plan for your individual needs.
Want to learn more about preventative healthcare initiatives? Find your local GP and explore available services.
